652997-57-4

Basic information

• Product Name: Methanesulfonic acid, trifluoro-, 4-cyano-2-methoxyphenyl ester
• CAS NO: 652997-57-4
• Molecular Formula: C9H6F3NO4S
• Molecular Weight: 281.212
• Mol File: 652997-57-4.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Methanesulfonic acid, trifluoro-, 4-cyano-2-methoxyphenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid, trifluoro-, 4-cyano-2-methoxyphenyl ester(652997-57-4)
• EPA Substance Registry System: Methanesulfonic acid, trifluoro-, 4-cyano-2-methoxyphenyl ester(652997-57-4)

Safety Data

• Hazardous Substances Data: 652997-57-4(Hazardous Substances Data)

Upstream product

• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 1025373-45-8 trifluoromethanesulfonic acid anhydride 
• 421-83-0 trifluoromethane sulfonyl chloride 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 914106-32-4 4-(3-hydroxy-3-methylbut-1-ynyl)-3-methoxybenzonitrile 
• 652997-58-5 (E)-methyl-3-(4-cyano-2-methoxyphenyl)acrylate 
• 949892-14-2 3-methoxy-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2yl)benzonitrile 
• 959934-76-0 tert-butyl (2E)-3-(4-cyano-2-methoxyphenyl)acrylate 

Relevant articles and documents

Efficient cross-coupling of aryl/alkenyl triflates with acyclic secondary alkylboronic acids

Aryl-secondary alkyl cross-coupling with aryl sulfonate esters as coupling partners remains a significant challenge. Efficient cross-coupling between aryl/alkenyl triflates and acyclic secondary alkylboronic acids is realized for the first time to provide a series of sterically congested acyclic secondary alkyl arenes/olefins in good to excellent yields. The employment of sterically bulky P,PO ligand L1/L2 is crucial for the high yields and selectivities. The method has enabled a concise and 4-step synthesis of a key intermediate of male contraceptive agent and PAF antagonist gossypol.

Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout

To test the hypothesis that inhibitors of human concentrative nucleoside transporter 2 (hCNT2) suppress increases in serum urate levels derived from dietary purines, we previously identified adenosine derivative 1 as a potent hCNT2 inhibitor (IC50 = 0.64 μM), but further study was hampered due to its poor solubility. Here we describe the results of subsequent research to identify more soluble and more potent hCNT2 inhibitors, leading to the discovery of the benzimidazole nucleoside 22, which is the most potent hCNT2 inhibitor (IC50 = 0.062 μM) reported to date. Compound 22 significantly suppressed the increase in plasma uric acid levels after oral administration of purine nucleosides in rats. Because compound 22 was poorly absorbed orally in rats (F = 0.51%), its pharmacologic action was mostly limited to the gastrointestinal tract. These findings suggest that inhibition of hCNT2 in the gastrointestinal tract can be a promising approach for the treatment of hyperuricemia.

SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.